ATC Group: M05BA08 Zoledronic acid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M05BA08 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M05 Drugs for treatment of bone diseases
3 M05B Drugs affecting bone structure and mineralization
4 M05BA Bisphosphonates
5 M05BA08 Zoledronic acid

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
PAREN Parenteral 4 mg

Active ingredients in M05BA08

Active Ingredient

Zoledronic acid belongs to the class of bisphosphonates and acts primarily on bone. It is an inhibitor of osteoclastic bone resorption.

Related product monographs

Document Type Information Source  
 ZERLINDA Solution for infusion MPI, EU: SmPC Health Products Regulatory Authority (IE)
 ZOBONE Concentrate for solution for infusion MPI, Generic Health Products Regulatory Authority (ZA)

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Romania (RO)

Tunisia (TN)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.